At the European Society of Cardiology (ESC) Congress 2025, researchers presented new evidence on the role of remote ischemic preconditioning (RIPC) in patients undergoing isolated valve replacement surgery. The meta-analysis, conducted by an international team led by Dr. N. Patel from the All India Institute of Medical Sciences, Jodhpur, evaluated whether RIPC, a technique involving short cycles of limb ischemia and reperfusion could protect the heart against surgery-induced damage.

The analysis included nine studies with a combined cohort of 1,269 patients (636 RIPC; 633 control). Findings revealed that RIPC significantly reduced myocardial injury markers, lowering CK-MB levels (SMD: -0.24; p = 0.008) and cardiac troponin I levels (SMD: -2.09; p = 0.0001). Patients receiving RIPC also required shorter durations of invasive ventilation (MD: -0.78 hours; p = 0.03), suggesting improved cardiopulmonary resilience.

However, the protective effects did not translate into broader clinical benefits. No significant differences were observed in the risk of acute kidney injury (RR: 0.95; p = 0.57), ICU stay duration, or overall hospital length of stay.

The study adds weight to ongoing debates about RIPC’s utility in cardiac surgery. Its findings suggest that while the intervention may be a promising adjunct for myocardial protection, its role in improving overall patient recovery requires more definitive investigation.